Delivery Order SPE2DR25D3103-SPE2DR26F9P10
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,691.55 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) with a firm fixed price contract type and an ultimate completion date of September 16, 2025. This non-set-aside, competitively awarded delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with...
- The Defense Logistics Agency awarded a delivery order valued at $15,850.71 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) on a firm fixed price basis. The order, with a completion deadline of November 6, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,439.79 to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count packaging) with a completion date of June 20, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed-price delivery order issued on June 18, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $23,536.24 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) under a firm fixed-price contract structure. The award, issued on December 1, 2025, with an ultimate completion date of December 2, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,863.01 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count package). This is a firm fixed price, non-set-aside contract with an ultimate completion date of November 28, 2025, and was awarded on November 26, 2025. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,774.43 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count packages) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement executed under a non-set-aside designation. The award is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency valued at $3,864.33 for the supply of Entecavir 0.5 mg tablets (30-count units). This firm fixed price delivery order was issued on September 18, 2025, with an ultimate completion date of September 19, 2025, and represents a non-set-aside, competitively awarded contract. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Entecavir 0.5 mg tablets (30-count) with a ceiling value of $3,389.37. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by December 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside competitive award, this contract reflects AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,832.16 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Entecavir 0.5 mg tablets in a 30-count package. This is a firm fixed-price, non-set-aside contract with a completion date of July 22, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Entecavir 0.5 mg tablets in quantities of 30 units. This contract, valued at $2,631.62, represents a firm fixed price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9P10Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,229.28 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) with a completion date of December 15, 2025. This competitively awarded, non-set-aside contract was issued on December 12, 2025, under a firm fixed-price arrangement with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a standard pharmaceutical procurement supporting the federal government's medical supply needs. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $1 billion through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a broad range of medications and medical commodities to support military healthcare programs and other federal medical systems. The company's federal contract portfolio demonstrates its capability to meet diverse pharmaceutical procurement requirements, spanning from specialty medications to generic drugs and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 12/11/25 |